ClinicalTrials.gg
RecruitingNCT07570446CMT-autonomUpdated May 6, 2026

AUTONOMOUS DISORDERS IN CMT

An observational study in CMT - Charcot-Marie-Tooth Disease, CMT1A and CMT (Charcot Marie Tooth Disease), sponsored by University Medical Center Goettingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University Medical Center Goettingen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Hereditary neuropathies are a phenotypically and genetically heterogeneous group of disorders. One of the most common forms is Charcot-Marie-Tooth neuropathy (CMT), which can be further divided into demyelinating (CMT1) and axonal (CMT2) neuropathies, as well as various pathogenic genetic variants. In addition to the clinically predominant motor and sensory deficits, symptoms of the autonomic nervous system have also been described in patients with CMT, often leading to significant limitations in daily functioning and quality of life. However, little is known about the prevalence and extent of autonomic dysfunction in CMT patients.

In this study, patients with CMT will be assessed for the presence, severity, and characteristics of autonomic dysfunction using questionnaires and non-invasive diagnostic methods. Furthermore, diagnosis, genotype, and individual disease data-such as disease duration, severity of neurological impairment, and comorbidities-will be collected from patient records.

The aim of this study is to evaluate and characterize autonomic dysfunction in patients with CMT. It seeks to determine how frequently autonomic dysfunction occurs in CMT, which areas of the autonomic nervous system are most commonly affected, whether risk factors exist, and what differences can be observed between the various CMT subtypes. The findings of this study are expected to provide new insights into the role of autonomic dysfunction in CMT, ultimately contributing to improved care and treatment for affected patients.

02

Conditions studied

  • CMT - Charcot-Marie-Tooth Disease
  • CMT1A
  • CMT (Charcot Marie Tooth Disease)
03

In context

Charcot-Marie-Tooth Disease

115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.

This study's planned enrollment of 50 is below the median of 120 across 49 observational studies indexed under Charcot-Marie-Tooth Disease.

Browse Charcot-Marie-Tooth Disease studies →

Lead sponsor

University Medical Center Goettingen is the lead sponsor of 62 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants from the Biomarkers and Validation of Selected Outcome Measures (CMTNSmod) study (ClinicalTrials.gov ID NCT03386266)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical CMT Diagnosis / Anamnestically Healthy Control Group
  • Genetic confirmation of CMT in adult patients
  • Ability to achieve the outcome measure at baseline
  • Age between 18 and 65 years
  • Capacity of all study participants to consent and signed , - including patient or participant information and consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding period
  • Other relevant neurological or psychiatric disorders, acute or in the past history
  • Presence of a serious previous internal disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • CMT patients
  • Controls

    Healthy age-matched controls

06

What researchers measure

Primary outcomes

  1. COMPASS 31

    validated questionaire

    Time frame: baseline

  2. electrophysiological measurement

    Validated electrophysiological examinations including the sympathetic skin reflex, the Schellong test, and heart rate variability measurement

    Time frame: baseline

Secondary outcomes

  1. muscle strength

    Time frame: baseline

  2. neurography

    Examinations measuring the electrical activity and conductivity of nerves, which are used to diagnose nerve damage or diseases.

    Time frame: baseline

  3. nerve sonography

    Time frame: at visit

07

Study locations

1 of 1 sites recruiting
  • University Medical Centre
    Göttingen, Lower Saxony 37075, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 6, 2026
StartActual
Jul 30, 2024
Primary completionEst.
Jul 5, 2026
CompletionEst.
Jul 30, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570446
Lead sponsor
University Medical Center Goettingen
Responsible party
Michael W Sereda, MD, Professor of Neurology (Prof. Michael Sereda MD, University Medical Center Goettingen) — Principal investigator
First posted
May 6, 2026
Start date
Jul 30, 2024
Primary completion
Jul 5, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Michael W Sereda, Prof. MD
Contact
sereda@mpinat.mpg.de
+49 551 3964162

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion